A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).

The trial includes a 13-15 week run-in period prior to randomization, and a 26-week,
double-blind, placebo-controlled treatment period (Phase A) followed by a 78-week
double-blind, extension period (Phase B).

Inclusion Criteria:

- Diagnosis of T2DM in accordance to American Diabetes Association guidelines

- Participants must be receiving metformin monotherapy for less than 8 weeks prior to
study participation or require change in their diabetes regimen to remain eligible to
participate in the trial (including discontinuing anti-hyperglycemic agent [AHA]
therapy) and must have a hemoglobin A1c of 7.0 to 10.5% (53-91 mmol/mol) after at
least 8 weeks on a regimen of metformin monotherapy

Exclusion Criteria: - History of myocardial infarction, unstable angina, arterial
revascularization, stroke, transient ischemic attack, or New York Heart Association (NYHA)
functional class III-IV heart failure within 3 months of study participation

- A clinically significant electrocardiogram abnormality

- A history of malignancy ≤5 years prior to study participation, except for adequately
treated basal or squamous cell skin cancer or in situ cervical cancer

- A known hypersensitivity or intolerance to any sodium-glucose co-transporter 2
(SGLT2) inhibitor or glimepiride

- On a blood pressure or lipid altering medication that have not been on a stable dose
for at least 4 weeks prior to study participation

- A surgical procedure within 6 weeks prior to study participation or planned major
surgery during the trial

- Donation of blood or blood products within 6 weeks of study participation or plans to
donate blood or blood products at any time during the trial

- Pregnant or breast-feeding, or is expecting to conceive during the trial, including
14 days following the last dose of study drug